| Filed On | Filing |
|---|---|
| 16 Nov 2026 |
Form 4: Torley Helen, Director
Received 20,000 shares by exercise or conversion ($368K) · Sold 20,000 shares ($2.03M) · Received 20,000 shares by exercise or conversion ($336K) · 3 more |
| 05 Nov 2026 | 10-Q |
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
Total Revenue of $1.860 - $1.925 billion, YOY Growth of 33% - 38% |
| 08 Oct 2026 |
Form 4: Torley Helen, Director
Received 20,000 shares by exercise or conversion ($368K) · Sold 20,000 shares ($2.19M) · Received 20,000 shares by exercise or conversion ($368K) · 3 more |
| 08 Oct 2026 |
Form 4/A: Connaughton Bernadette, Director
Received 3,796 shares as a grant or award |
| 02 Oct 2026 |
Form 4: Daly James M, Director
Received 1,169 shares as a grant or award · Granted 1,775 Option to Purchase Common Stock |
| 02 Oct 2026 |
Form 3: Daly James M, Director
No securities owned |
| 02 Oct 2026 |
Form 4: Posard Matthew L., Director
Sold 5,230 shares ($568K) |
| 30 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
(d) On September 28, 2026, James Daly was elected to the Board of Directors of Halozyme Therapeutics, Inc. (the “Company”). Mr. Daly was elected to the class of directors with terms ending at the Company’s annual meeting of stockholders ... |
| 22 Sep 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more
INDENTURE, dated as of September 22, 2026, between Halozyme Therapeutics, Inc., a Delaware corporation, as issuer (the “Company”), and The Bank of New York Mellon Trust Company, N.A., not in its individual capacity but solely as trustee,... |
| 18 Sep 2026 |
8-K: Other Events
Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033 |
| 17 Sep 2026 |
Form 4: Posard Matthew L., Director
Sold 18,996 shares ($2.05M) |
| 16 Sep 2026 | 144 |
| 16 Sep 2026 |
8-K: Other Events
SAN DIEGO, CA, September 16, 2026 — Halozyme Therapeutics, Inc. (Nasdaq: HALO) (“Halozyme” or the “Company”), today announced that it intends to offer, subject to market conditions and other factors, $1.05 billion aggregate principal amo... |
| 11 Sep 2026 |
Form 4: Torley Helen, Director
Received 20,000 shares by exercise or conversion ($368K) · Sold 20,000 shares ($2.15M) · Received 20,000 shares by exercise or conversion ($368K) · 3 more |
| 02 Sep 2026 |
Form 4: Appelhans Dannielle, Director
Received 1,161 shares as a grant or award · Granted 1,778 Option to Purchase Common Stock |
| 21 Aug 2026 |
Form 3: Appelhans Dannielle, Director
No securities owned |
| 19 Aug 2026 |
Form 4: Torley Helen, Director
Received 20,000 shares by exercise or conversion ($368K) · Sold 20,000 shares ($2.05M) · Received 20,000 shares by exercise or conversion ($368K) · 3 more |
| 18 Aug 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
(d) On August 14, 2026, Dannielle Appelhans was elected to the Board of Directors of Halozyme Therapeutics, Inc. (the “Company”). Ms. Appelhans was elected to the class of directors with terms ending at the Company’s annual meeting of st... |
| 17 Aug 2026 | 144 |
Loading...